ReviewDrugs2012
Topical testosterone supplementation for the treatment of male hypogonadism.
Review in Drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Evaluation of an Anhydrous Permeation-Enhancing Vehicle for Percutaneous Absorption of Hormones.AAPS PharmSciTech · 2022Article
- Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age.Andrology · 2022Review
- Hypogonadism in Adult Males with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion.Journal of clinical medicine · 2021Article
- Conversion of Fibroblast into Functional Leydig-like Cell Using Defined Small Molecules.Stem cell reports · 2020Article
- Leydig cells: formation, function, and regulation.Biology of reproduction · 2018Review
- Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone.Journal of the Endocrine Society · 2017Article
- Atypical major depressive episode as initial presentation of intracranial germinoma in a male adolescent.Neuropsychiatric disease and treatment · 2017Article
- Age and testosterone mediate influenza pathogenesis in male mice.American journal of physiology. Lung cellular and molecular physiology · 2016Article
- Pharmacology of testosterone replacement therapy preparations.Translational andrology and urology · 2016Review
- Issues Surrounding Testosterone Replacement Therapy.Hospital pharmacy · 2016Article
- Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness.Translational andrology and urology · 2016Review
- The practical management of testosterone deficiency in men.Nature reviews. Urology · 2015Review
- Leydig cell aging and hypogonadism.Experimental gerontology · 2015Review
- Transdermal testosterone replacement therapy in men.Drug design, development and therapy · 2014Review
- Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells.Endocrinology · 2013Article
- Effectiveness of Panax ginseng on Acute Myocardial Ischemia Reperfusion Injury Was Abolished by Flutamide via Endogenous Testosterone-Mediated Akt Pathway.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- The effect of metabolic syndrome upon the success of varicocelectomy.TheScientificWorldJournal · 2012Article
- Selective androgen receptor modulators for the treatment of late onset male hypogonadism.Asian journal of andrologyReview
- Efficacy of Fixed Low-Dose Weekly Subcutaneous Testosterone Self-Administration in Transgender Male Patients in India.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related hormonal decline is gradual and less recognized in men than in women. Symptoms are oftentimes ignored and non-specific. Fatigue, lack of concentration, mood swings, decreased sexual desire, erectile dysfunction, infertility, hair loss, reduced muscle and bone mass, and weight gain are a few of the symptoms of male hypogonadism. This disorder is linked to reduction in quality of life, and poorer health outcomes as it may increase the risk for cardiovascular disease, diabetes mellitus, metabolic syndrome, Alzheimer's disease and premature death. Different modalities of testosterone replacement therapy have evolved over 70 years, and sales continue to grow. Each preparation is differentiated by route of delivery, ease of use, cost and pharmacokinetics. Topical/transdermal testosterone replacement therapy, including patches and gels, are the most modern formulations on the market. These are more expensive treatments, but yield more physiological concentrations of testosterone. Restoration of testosterone levels to the eugonadal range reverses signs and symptoms of hypogonadism, except for infertility, and may alleviate co-morbidities associated with hypogonadism. Patient understanding of and compliance with both treatment and monitoring are of utmost importance to achieve clinical success with maximum benefit and minimum risk. The aim of our review is to summarize the indications, contraindications, benefits and risks of testosterone replacement therapy as they relate to transdermal administration. Further, we compare the various testosterone preparations, focusing on the newest topical/transdermal routes of administration that are currently available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.